Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous

We love to hear from our listeners. Send us a message. On episode 136 of Cell & Gene: The Podcast, Host Erin Harris welcomes back Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath to discuss why autoimmune CAR T is moving rapidly from an emerging concept toward a potentially transformative treatment approach. They talk about the very different benefit-risk calculus in autoimmune disease compared with oncology, the patient and caregiver burden of conditioning, apheresis and long-term monitoring, and the need to rethink clinical trial endpoints around meaningful outcomes. They explore the potential of in vivo CAR T and circular RNA to eliminate some of the biggest barriers in the current treatment pathway, while discussing the scientific and durability questions that remain. Subscribe to the podcast! Apple  |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn